IntelGenx is in the clinical stage of integrating Montelukast into an oral film with encouraging results showing the ability to restore learning and memory in vivo.
Alzheimer's disease currently has very few treatment options, with none treating the underlying pathophysiology. Therefore, any advancements in this field are important, and the fact that Montelukast is disease-modifying would be of huge significance.
If oral films as a method to increase bioavailability was used for other drugs, there may be more accounts like this, saving drug development from failure or existing drugs that gain a new use.
News 
Market Data 
Discover 
